TGFβ, activin and SMAD signalling in thyroid cancer;TGFβ, activina e sinalização SMAD em câncer de tiróide

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 51, Issue 5, 2007, Pages 683-689

  Kimura, Edna T ^a   Matsuo, Sílvia E ^a   Ricarte Filho, Júlio Cézar ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Activin; SMAD signalling; Smurf; TGF ; Thyroid cancer; Tumor progression

Indexed keywords

ACTIVIN; DNA BINDING PROTEIN; GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; SMAD PROTEIN; SMAD7 PROTEIN; SMAD7 PROTEIN, HUMAN; SMURF2 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

CELL LINE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; THYROID TUMOR;

ACTIVINS; CELL LINE; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RECEPTORS, GROWTH FACTOR; SIGNAL TRANSDUCTION; SMAD PROTEINS; SMAD7 PROTEIN; THYROID NEOPLASMS; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN-PROTEIN LIGASES;

EID: 35348830400     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302007000500005     Document Type: Review

References (58)

1. Massague J. TGFβ signal transduction. Annu Rev Biochem 1998;67:753-91.
2. Heldin CH, Miyazono K, ten Dijke P. TGFβ signalling from cell membrane to nucleus through SMAD proteins. Nature 1997;390:465-71.
3. Izzi L, Attisano L. Regulation of the TGFβ signalling pathway by ubiquitin-mediated degradation. Oncogene 2004;23:2071-8.
4. Matsuo SE, Martins L, Leoni SG, Hajjar D, Ricarte-Filho JCM, Ebina KN, et al. Marcadores biológicos de tumores tiroidianos. Arq Bras Endocrinol Metab 2004;48:114-25.
5. Anzano MA, Roberts AB, Meyers CA, Komoriya A, Lamb LC, Smith JM, et al. Synergistic interaction of two classes of transforming growth factors from murine sarcoma cells. Cancer Res 1982;42:4776-8.
6. Massague J, Blain SW, Lo RS. TGFβ signaling in growth control, cancer, and heritable disorders. Cell 2000;103:295-309.
7. Roberts AB, Sporn MB. The transforming growth factor beta. Peptide Growth Factors and their Receptors. Heidelberg: Springer-Verlag, 1990. pp. 419-72.
8. Ling N, Ying SY, Ueno N, Shimasaki S, Esch F, Hotta M, et al. Pituitary FSH is released by a heterodimer of the β-subunits from the two forms of inhibin. Nature 1986;321:779-82.
9. Vale W, Rivier J, Vaughan J, McClintock R, Corrigan A, Woo W, et al. Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature 1986;321:776-9.
10. Pangas SA, Woodruff TK. Activin signal transduction pathways. Trends Endocrinol Metab 2000;11:309-14.
11. Wrana JL, Attisano L. The Smad pathway. Cytokine Growth Factor Rev 2000;11:5-13.
12. Matzuk MM, Kumar TR, Vassalli A, Bickenbach JR, Roop DR, Jaenisch R, et al. Functional analysis of activins during mammalian development. Nature 1995;374:354-6.
13. Geng Y, Weinberg RA. Transforming growth factor beta effects on expression of G1 cyclins and cyclin-dependent protein kinases. Proc Natl Acad Sci U S A 1993;90:10315-9.
14. Warner BJ, Blain SW, Seoane J, Massague J. Myc downregulation by transforming growth factor beta required for activation of the p15(Ink4b) G(1) arrest pathway. Mol Cell Biol 1999;19:5913-22.
15. Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer. J Clin Oncol 2005;23:2078-93.
16. Boitani C, Stefanini M, Fragale A, Morena AR. Activin stimulates Sertoli cell proliferation in a defined period of rat testis development. Endocrinology 1995;136:5438-44.
17. Miro F, Hillier SG. Modulation of granulosa cell deoxyribonucleic acid synthesis and differentiation by activin. Endocrinology 1996;137:464-8.
18. Chen Y-G, Lui HM, Lin S-L, Lee JM, Ying S-Y. Regulation of cell proliferation, apoptosis, and carcinogenesis by activin. Exp Biol Med (Maywood);227:75-87.
19. Zauberman A, Oren M, Zipori D. Involvement of p21(WAF1/Cip1), CDK4 and Rb in activin A mediated signaling leading to hepatoma cell growth inhibition. Oncogene 1997;15:1705-11.
20. Sehy DW, Shao LE, Yu AL, Tsai WM, Yu J. Activin A-induced differentiation in K562 cells is associated with a transient hypophosphorylation of RB protein and the concomitant block of cell cycle at G1 phase. J Cell Biochem 1992;50:255-65.
21. Gold LI. The role for transforming growth factor-beta (TGFβ) in human cancer. Crit Rev Oncog 1999;10:303-60.
22. Lu S-L, Reh D, Li AG, Woods J, Corless CL, Kulesz-Martin M, et al. Overexpression of transforming growth factor β1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res 2004;64:4405-10.
23. Muraoka-Cook RS, Dumont N, Arteaga CL. Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin Cancer Res 2005;11:937s-43s.
24. Levy L, Hill CS. Alterations in components of the TGFβ superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 2006;17:41-58.
25. Kaklamani VG, Hou N, Bian Y, Reich J, Offit K, Michel LS, et al. TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies. J Clin Oncol 2003;21:3236-43.
26. Pasche B, Knobloch TJ, Bian Y, Liu J, Phukan S, Rosman D, et al. Somatic acquisition and signaling of TGFBR1*6A in cancer. JAMA 2005;294:1634-46.
27. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-3.
28. Fleisch MC, Maxwell CA, Barcellos-Hoff MH. The pleiotropic roles of transforming growth factor beta in homeostasis and carcinogenesis of endocrine organs. Endocr Relat Cancer 2006;13:379-400.
29. Lazzereschi D, Nardi F, Turco A, Ottini L, D'Amico C, Mariani-Costantini R, et al. A complex pattern of mutations and abnormal splicing of Smad4 is present in thyroid tumours. Oncogene 2005;24(34):5344-54.
30. Zhu Y, Richardson JA, Parada LF, Graff JM. Smad3 mutant mice develop metastatic colorectal cancer. Cell 1998;94:703-14.
31. - symporter messenger RNA and protein levels in FRTL-5 rat thyroid cells. Thyroid 1997;7:789-94.
32. Morris JC, 3rd, Ranganathan G, Hay ID, Nelson RE, Jiang NS. The effects of transforming growth factor-beta on growth and differentiation of the continuous rat thyroid follicular cell line, FRTL-5. Endocrinology 1988;123:1385-94.
33. Asmis LM, Kaempf J, Von Gruenigen C, Kimura ET, Wagner HE, Studer H. Acquired and naturally occurring resistance of thyroid follicular cells to the growth inhibitory action of transforming growth factor-beta 1 (TGFβ 1). J Endocrinol 1996;149:485-96.
34. Colletta G, Cirafici AM, Di Carlo A. Dual effect of transforming growth factor beta on rat thyroid cells: inhibition of thyrotropin-induced proliferation and reduction of thyroid-specific differentiation markers. Cancer Res 1989;49:3457-62.
35. Costamagna E, Garcia B, Santisteban P. The functional interaction between the paired domain transcription factor Pax8 and Smad3 is involved in transforming growth factor-beta repression of the sodium/iodide symporter gene. J Biol Chem 2004;279:3439-46.
36. Gartner R, Schopohl D, Schaefer S, Dugrillon A, Erdmann A, Toda S, et al. Regulation of transforming growth factor beta 1 messenger ribonucleic acid expression in porcine thyroid follicles in vitro by growth factors, iodine, or delta-iodolactone. Thyroid 1997;7:633-40.
37. Cowin AJ, Davis JR, Bidey SP. Transforming growth factor-beta 1 production in porcine thyroid follicular cells: regulation by intrathyroidal organic iodine. J Mol Endocrinol 1992;9:197-205.
38. Holting T, Zielke A, Siperstein AE, Clark OH, Duh QY. Transforming growth factor-beta 1 is a negative regulator for differentiated thyroid cancer: studies of growth, migration, invasion, and adhesion of cultured follicular and papillary thyroid cancer cell lines. J Clin Endocrinol Metab 1994;79:806-13.
39. Ohta K, Pang XP, Berg L, Hershman JM. Antitumor actions of cytokines on new human papillary thyroid carcinoma cell lines. J Clin Endocrinol Metab 1996;81:2607-12.
40. Usa T, Tsukazaki T, Namba H, Ohtsuru A, Kimura H, Villadolid MC, et al. Correlation between suppression of c-myc and antiproliferative effect of transforming growth factor-beta 1 in thyroid carcinoma cell growth. Endocrinology 1994;135:1378-84.
41. Franzen A, Piek E, Westermark B, ten Dijke P, Heldin NE. Expression of transforming growth factor-beta1, activin A, and their receptors in thyroid follicle cells: negative regulation of thyrocyte growth and function. Endocrinology 1999;140:4300-10.
42. Kotajima A, Miyamoto Y, Tsuruo M, Kosaka M, Saito S. Effects of activin A on deoxyribonucleic acid synthesis, iodine metabolism, and cyclic adenosine monophosphate accumulation in porcine thyroid cells. Endocrinology 1995;136:1214-8.
43. Schulte KM, Jonas C, Krebs R, Roher HD. Activin A and activin receptors in thyroid cancer. Thyroid 2001;11:3-14.
44. Matsuo SE, Leoni SG, Colquhoun A, Kimura ET. Transforming growth factor-beta1 and activin A generate antiproliferative signaling in thyroid cancer cells. J Endocrinol 2006;190:141-50.
45. Kimura ET, Kopp P, Zbaeren J, Asmis LM, Ruchti C, Maciel RM, et al. Expression of transforming growth factor β1, β2, and β3 in multinodular goiters and differentiated thyroid carcinomas: a comparative study. Thyroid 1999;9:119-25.
46. Matsuo SE, Ebina KN, Kulcsar MA, Friguglietti CU, Kimura ET. Activin βB expression in rat experimental goiter and human thyroid tumors. Thyroid 2003;13:239-47.
47. Heldin NE, Bergstrom D, Hermansson A, Bergenstrahle A, Nakao A, Westermark B, et al. Lack of responsiveness to TGFβ1 in a thyroid carcinoma cell line with functional type I and type II TGFβ receptors and Smad proteins, suggests a novel mechanism for TGFβ insensitivity in carcinoma cells. Mol Cell Endocrinol 1999;153:79-90.
48. Cerutti JM, Ebina KN, Matsuo SE, Martins L, Maciel RM, Kimura ET. Expression of Smad4 and Smad7 in human thyroid follicular carcinoma cell lines. J Endocrinol Invest 2003;26:516-21.
49. Nakao A, Afrakhte M, Moren A, Nakayama T, Christian JL, Heuchel R, et al. Identification of Smad7, a TGFβ-inducible antagonist of TGFβ signalling. Nature 1997;389:631-5.
50. Afrakhte M, Moren A, Jossan S, Itoh S, Sampath K, Westermark B, et al. Induction of inhibitory Smad6 and Smad7 mRNA by TGFβ family members. Biochem Biophys Res Commun 1998;249:505-11.
51. Wang T. The 26S proteasome system in the signaling pathways of TGFβ superfamily. Front Biosci 2003;8:d1109-27.
52. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998;67:425-79.
53. Hartmann-Petersen R, Seeger M, Gordon C. Transferring substrates to the 26S proteasome. Trends Biochem Sci 2003;28:26-31.
54. Ebisawa T, Fukuchi M, Murakami G, Chiba T, Tanaka K, Imamura T, et al. Smurf1 interacts with transforming growth factor-beta type I receptor through Smad7 and induces receptor degradation. J Biol Chem 2001;276:12477-80.
55. Moren A, Imamura T, Miyazono K, Heldin CH, Moustakas A. Degradation of the tumor suppressor Smad4 by WW and HECT domain ubiquitin ligases. J Biol Chem 2005;280:22115-23.
56. Koinuma D, Shinozaki M, Komuro A, Goto K, Saitoh M, Hanyu A, et al. Arkadia amplifies TGFβ superfamily signalling through degradation of Smad7. Embo J 2003;22:6458-70.
57. Ricarte-Filho JCM, Kimura ET. Expressão gênica e imunohistoquímica das E3 ubiquitina-ligases SMURF1 e SMURF2 em carcinomas tiroidianos. Arq Bras Endocrinol Metab 2005;49(supl 1):S77.
58. Dumont N, Bakin AV, Arteaga CL. Autocrine transforming growth factor-beta signaling mediates Smad-independent motility in human cancer cells. J Biol Chem 2003;278:3275-85.